Correction: DanCann Pharma A/S Completes Issuance (2) of New Shares from Debt Conversion under the 10-Year Financing Loan-Agreement with 12-months Conversion Option with Nordic Growth Opportunities 2
Correction of earlier press release published today: In the earlier press release issued today, the following statement was provided: "As a consequence of the issue of new shares, the total debt under the instrument is reduced from DKK 6,600,000 (first tranche of the loans) to DKK 6,100,000." This statement has been corrected to: "As a consequence of the issue of new shares, the total debt under the instrument is reduced from DKK 6,100,000 (first tranche of the loans) to DKK 5,650,000." COPENHAGEN, Denmark, 18 August 2023 – DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma"